Table 1.
Characteristics of patients diagnosed with parotid cancers in NCR in 1999–2018.
| Years | 1999–2003 | 2004–2008 | 2009–2013 | 2014–2018 | All | p-Value |
|---|---|---|---|---|---|---|
| Total number of selected parotid gland cancers | 460 | 548 | 644 | 666 | 2318 | 0.027 |
| Demographic characteristics | ||||||
| Mean age ± SD | 57.9 ± 15.2 | 60.4 ± 16.5 | 63.1 ± 15.7 | 62.8 ± 16.4 | 61.3 ± 16.1 | 0.075 |
| Women (%) | 209 (45.4%) | 248 (45.3%) | 274 (42.6%) | 313 (47%) | 1044 (45%) | 0.442 |
| Men (%) | 251 (54.6%) | 300 (54.7%) | 370 (57.4%) | 353 (53%) | 1274 (55%) | |
| Urban citizens (%) | 311 (67.6%) | 340 (62%) | 404 (62.7%) | 430 (64.6%) | 1485 (64%) | 0.256 |
| Rural citizens (%) | 149 (32.4%) | 208 (38%) | 240 (37.3%) | 236 (35.4%) | 833 (36%) | |
| Histopathological diagnosis | ||||||
| Adenoid cystic carcinoma | 63 (13.7%) | 62 (11.3%) | 75 (11.7%) | 62 (9.3%) | 262 (11.3%) | 0.148 |
| Mucoepidermoid carcinoma | 57 (12.4%) | 87 (15.9%) | 93 (14.4%) | 81 (12.2%) | 318 (13.7%) | 0.214 |
| Adenocarcinoma | 104 (22.6%) | 118 (21.5%) | 104 (16.2%) | 128 (19.2%) | 454 (19.6%) | 0.031 |
| Squamous cell carcinoma | 131 (28.5%) | 168 (30.7%) | 244 (37.9%) | 229 (34.4%) | 772 (33.3%) | 0.005 |
| Acinar cell carcinoma | 30 (6.5%) | 45 (8.2%) | 59 (9.2%) | 66 (9.9%) | 200 (8.6%) | 0.228 |
| Carcinoma in pleomorphic adenoma | 75 (16.3%) | 68 (12.4%) | 69 (10.7%) | 100 (15%) | 312 (13.5%) | 0.026 |
| Clinical stage | ||||||
| Regional | 264 (57.4%) | 308 (56.2%) | 342 (53.1%) | 384 (57.7%) | 1298 (56%) | 0.347 |
| Locoregional | 156 (33.9%) | 181 (33%) | 231 (35.9%) | 212 (31.8%) | 780 (33.6%) | 0.472 |
| Systemic | 40 (8.7%) | 59 (10.8%) | 71 (11%) | 70 (10.5%) | 240 (10.4%) | 0.616 |
| Therapy | ||||||
| Only surgery | 107 (23.3%) | 127 (23.2%) | 162 (25.2%) | 219 (32.9%) | 615 (26.5%) | <0.001 |
| Only radiotherapy | 32 (7%) | 48 (8.8%) | 91 (14.1%) | 95 (14.3%) | 266 (11.5%) | <0.001 |
| Surgery + radiotherapy | 243 (52.8%) | 274 (50%) | 259 (40.2%) | 200 (30%) | 976 (42.1%) | <0.001 |
| Surgery + chemotherapy + radiotherapy | 37 (8%) | 38 (6.9%) | 51 (7.9%) | 28 (4.2%) | 154 (6.6%) | 0.022 |
| Others | 41 (8.9%) | 61 (11.1%) | 81 (12.6%) | 124 (18.6%) | 307 (13.2%) | <0.001 |